Business
Actinium is a clinical-stage biopharma company developing targeted radiotherapies for oncology, including solid tumor, hematology, and conditioning-agent programs.
Actinium revenue was only $90K; losses and FCF improved, but equity fell 76.1% and Altman-Z was distress.
The read at a glance✓ Audited against SEC data
- Business mix — Targeted radiotherapy oncology pipelineNote
- Revenue — Revenue was $90KNote
- Losses — Net loss narrowed to $33.9MOK
- Cash — FCF was -$24.7MWatch
- Balance sheet — Equity fell 76.1%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distressWatch
Where the revenue comes from
Fiscal 2025, as Actinium Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Other Revenue$90K
Leadership changes
From Actinium Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Steve O'Loughlin · Chief Financial Officer · departureeff. 2026-02-27
- Sandesh Seth · director · appointment
- Ajit S. Shetty · director · appointment
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Actinium Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.